Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial.
R. Hofheinz
Consultant or Advisory Role - Amgen; Merck KGaA; Roche
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Roche
F. K. Wenz
No relevant relationships to disclose
S. Post
No relevant relationships to disclose
A. Matzdorff
No relevant relationships to disclose
S. Laechelt
No relevant relationships to disclose
J. T. Hartmann
No relevant relationships to disclose
L. Müller
No relevant relationships to disclose
H. Link
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
M. H. Moehler
No relevant relationships to disclose
E. Kettner
No relevant relationships to disclose
E. Fritz
No relevant relationships to disclose
U. Hieber
No relevant relationships to disclose
H. W. Lindemann
No relevant relationships to disclose
M. Grunewald
No relevant relationships to disclose
S. Kremers
No relevant relationships to disclose
C. Constantin
No relevant relationships to disclose
M. Hipp
Consultant or Advisory Role - Merck KGaA
D. Gencer
No relevant relationships to disclose
I. Burkholder
No relevant relationships to disclose
A. Hochhaus
Research Funding - Roche